^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    letrozole

    i
    Other names: CGP 20267, CGS 20267, CGS20267
    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    1m
    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • fulvestrant • letrozole • Herzuma (trastuzumab-pkrb) • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • denifanstat (TVB-2640)
    1m
    EPIK-RO: Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Piqray (alpelisib) • fulvestrant • letrozole
    1m
    Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial (clinicaltrials.gov)
    P2, N=168, Not yet recruiting, Universitaire Ziekenhuizen KU Leuven
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    letrozole
    1m
    Tailoring Oncofertility to Breast Cancer Subtype: A Systematic Review of Fertility Preservation Strategies in Premenopausal Women. (PubMed, Cancers (Basel))
    Among studies with medium-term follow-up (3-5.5 years), no significant increase in recurrence or mortality attributable to FP was identified; long-term data beyond 5 years remain sparse. Substantial heterogeneity precluded meta-analysis; all synthesis is narrative. Standardized outco reporting and larger prospective subtype-stratified studies are required to establish precision oncofertility recommendations.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • HR positive • HR negative
    |
    tamoxifen • letrozole
    1m
    HARMONIA: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (clinicaltrials.gov)
    P3, N=61, Terminated, SOLTI Breast Cancer Research Group | N=456 --> 61 | Trial completion date: Mar 2027 --> Mar 2026 | Active, not recruiting --> Terminated; The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.
    Enrollment change • Trial completion date • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    Ibrance (palbociclib) • paclitaxel • Tevimbra (tislelizumab-jsgr) • Kisqali (ribociclib) • fulvestrant • letrozole
    1m
    Comparative Evaluation of Letrozole, L-Carnitine, and Combination Therapy on Sperm Quality and ART Outcomes in Idiopathic Oligoasthenoteratozoospermia: A Three-Arm Randomized Trial (clinicaltrials.gov)
    P2/3, N=90, Completed, Tehran University of Medical Sciences
    New P2/3 trial
    |
    letrozole
    2ms
    Bilateral panuveitis associated with letrozole therapy. (PubMed, Retin Cases Brief Rep)
    Letrozole-associated panuveitis has not previously been reported. This case highlights the importance of detailed medication history as well as the need for interdisciplinary collaboration when managing drug-induced uveitis. Early recognition and appropriate therapy can result in favorable visual outcomes.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    letrozole
    2ms
    RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer (clinicaltrials.gov)
    P2, N=110, Recruiting, Dana-Farber Cancer Institute | N=180 --> 110
    Enrollment change
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53)
    |
    ER positive • TP53 wild-type
    |
    Verzenio (abemaciclib) • letrozole • gedatolisib (PF-05212384) • metformin • samotolisib (LY3023414)
    2ms
    Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Novartis Pharmaceuticals | N=217 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HER-2 negative
    |
    fulvestrant • letrozole
    2ms
    Bone Health in Breast Cancer Patients: Comparative Evaluation Using Dual Energy X-Ray Absorptiometry Scan and High-Resolution Peripheral Quantitative Computed Tomography. (PubMed, J Bone Metab)
    HR-pQCT was superior to DXA in detecting microarchitectural deterioration in women with breast cancer. This pilot study emphasizes the need for larger prospective studies in Indian cohorts.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    EGFR positive
    |
    letrozole
    2ms
    Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (clinicaltrials.gov)
    P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    HercepTest
    |
    Verzenio (abemaciclib) • letrozole
    2ms
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • eribulin mesylate • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • giredestrant (RG6171) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)